Apple Breaks Through in Wearable Blood Pressure Monitoring
In what health technology analysts are calling the most significant FDA clearance for a consumer device in years, Apple announced today that its Watch Ultra 3 has received 510(k) clearance from the U.S. Food and Drug Administration for on-wrist blood pressure monitoring. The clearance makes the Apple Watch Ultra 3 the first mainstream consumer wearable capable of providing clinically validated blood pressure readings without a traditional inflatable cuff.
The feature, which will be activated through a watchOS update expected in May 2026, uses a combination of optical sensors and a new piezoelectric pressure sensor embedded in the Ultra 3's back crystal to measure arterial pulse wave velocity — the speed at which blood pressure waves travel through the arteries.
How the Technology Works
Traditional blood pressure monitoring relies on an inflatable cuff that temporarily occludes arterial blood flow. Apple's cuffless approach instead uses pulse transit time (PTT) measurement, which correlates the time delay between the heart's electrical activity and the arrival of the pulse wave at the wrist.
The Ultra 3 combines data from its enhanced photoplethysmography (PPG) sensors, the electrical heart sensor used for ECG readings, and the new piezoelectric element to calculate systolic and diastolic blood pressure. The system requires initial calibration using a standard cuff-based monitor, after which it can provide readings throughout the day without additional equipment.
- Readings are taken automatically every 20 minutes when the watch detects the wearer is stationary
- Users can also initiate on-demand readings at any time
- Data is stored in the Apple Health app with trend visualization and PDF export for sharing with physicians
- The system alerts users when readings exceed thresholds defined by their healthcare provider
Clinical Validation
Apple submitted data from a clinical trial involving 4,800 participants across 40 sites to support its FDA submission. The study compared Ultra 3 readings against simultaneous measurements from a validated reference sphygmomanometer (cuff-based monitor).
"The device met FDA accuracy standards with a mean difference of less than 5 mmHg for both systolic and diastolic readings, and a standard deviation below 8 mmHg," Apple stated in its regulatory filing.
These numbers align with the standards set by the Association for the Advancement of Medical Instrumentation (AAMI) for blood pressure monitoring devices. Importantly, the accuracy held across a diverse population including individuals with darker skin tones, varying body compositions, and common cardiovascular conditions.
Why This Matters for Public Health
Hypertension — high blood pressure — is often called the "silent killer" because it typically produces no symptoms until serious damage has occurred. According to the CDC, nearly half of American adults have hypertension, but only about one in four has it under control. The condition is a leading risk factor for heart attack, stroke, kidney disease, and dementia.
One of the biggest barriers to better blood pressure management is the inconvenience of traditional monitoring. Home cuff monitors require users to sit still for several minutes, and many people only have their blood pressure checked during infrequent doctor visits. Continuous, passive monitoring on a device people already wear could fundamentally change how hypertension is detected and managed.
Dr. Michael Blaha, director of clinical research at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, called the clearance "a genuine inflection point for preventive cardiology." He noted that continuous data could help physicians identify patterns like nocturnal hypertension and white coat hypertension that single office readings miss.
Limitations and Caveats
The FDA clearance comes with important limitations. The feature is cleared for adults aged 22 and older who do not have atrial fibrillation, severe peripheral artery disease, or arrhythmias other than occasional premature beats. Apple also notes that the feature is intended for health wellness purposes and is not a substitute for clinical diagnosis.
Recalibration with a standard cuff monitor is recommended every 28 days to maintain accuracy. The feature is exclusive to the Apple Watch Ultra 3 and will not be available on standard Apple Watch models or the SE line, as it requires hardware sensors not present in those devices.
Competitive Landscape
Samsung has been developing its own cuffless blood pressure feature for the Galaxy Watch line, though its current implementation — available in South Korea — has not received FDA clearance for the U.S. market. Google's Fitbit division and several startups are also working on similar technology.
The Apple Watch Ultra 3 retails for $899, placing it at the premium end of the wearable market. Whether the blood pressure feature alone justifies the price premium over standard models — or over a $30 home blood pressure cuff — will depend on how well it performs in real-world conditions over time.
